Work on identifying CDKN2A, as well as MGMT, as a measure of cancer risk and diagnosis was expanded in a 21-patient study of matched sputum and squamous cell carcinoma (SCC) samples as well as sputum samples from 32 patients evaluated for possible lung cancer. This evidence concerns the gene MGMT and cancer.